EMAIL THIS PAGE TO A FRIEND

Cutis

Amcinonide vs. betamethasone dipropionate ointments in the treatment of psoriasis.


PMID 3891239

Abstract

A randomized, double-blind study compared the efficacy and safety of amcinonide and betamethasone dipropionate ointments, applied twice daily for two weeks, in the treatment of patients with moderate to severe psoriasis. Thirty-four patients were enrolled; thirty patients had had psoriasis for more than one year, and in the majority of patients, it was stable or slowly exacerbating. Significant improvement from baseline was observed with both ointments at weeks 1 and 2. The two drugs showed comparable cosmetic acceptability. Adverse cutaneous symptoms experienced were burning (both groups), itching (amcinonide), and stinging (beta-methasone); no serious adverse effects were reported.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

A2428
Amcinonide, analytical standard
C28H35FO7